ONDANSETRON Syrup (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Ondansetron 4mg/5ml Syrup.
Qualitative and quantitative composition
Each 5ml contains 4mg of ondansetron as the hydrochloride dihydrate. Excipients with known effects: Ethanol (less than 3mg/dose) and sodium (less than 1mmol of per dose). For the full list of excipients, ...
Pharmaceutical form
Syrup. Clear strawberry flavoured liquid.
Therapeutic indications
Adults The management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention of post-operative nausea and vomiting in adults. Paediatric Population Ondansetron ...
Posology and method of administration
Posology Chemotherapy and radiotherapy induced nausea and vomiting (CINV) Adults The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concomitant use with apomorphine (see section 4.5).
Special warnings and precautions for use
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT<sub>3</sub> receptor antagonists. Respiratory events should be treated symptomatically ...
Interaction with other medicinal products and other forms of interaction
There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no pharmacokinetic interactions ...
Fertility, pregnancy and lactation
Pregnancy The safety of ondansetron for use in human pregnancy has not been established. Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the ...
Effects on ability to drive and use machines
Ondansetron has no or negligible influence on the ability to drive and use machines. In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities ...
Undesirable effects
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) ...
Overdose
Symptoms There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations ...
Pharmacodynamic properties
Pharmacotherapeutic group: Serotonin (5HT<sub>3</sub>) antagonists ATC code: A04AA Mechanism of action Ondansetron is a potent, highly selective 5HT<sub>3</sub> receptor-antagonist. Its precise mode of ...
Pharmacokinetic properties
Absorption Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30ng/ml ...
Preclinical safety data
No additional data of relevance.
List of excipients
Citric acid anhydrous Sodium citrate dihydrate Sodium benzoate (E211) Xylitol (E967) Strawberry flavour (contains propylene glycol and ethanol) Purified water
Incompatibilities
Not applicable.
Shelf life
Shelf life: 2 years unopened. Once opened, use within 28 days.
Special precautions for storage
No special requirements.
Nature and contents of container
A type III amber glass bottle with a tamper evident aluminium cap with an EPE liner, or a child resistant polypropylene cap with an EPE liner, containing 50ml.
Special precautions for disposal and other handling
No special requirements for disposal. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Focus Pharmaceuticals Ltd, Capital House, 1<sup>st</sup> Floor, 85 King William Street, London EC4N 7BL, United Kingdom
Marketing authorization number(s)
PL 20046/0036
Date of first authorization / renewal of the authorization
13/09/2011
Date of revision of the text
09/04/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
